Intellia (NTLA) Soars 13% to Fresh High
Earlier this month, Intellia Therapeutics, Inc.
Intellia Therapeutics Inc. (NTLA)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Bayforest Capital Theodoros Tsagaris | 262 | $4,525 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $10.03 | 100,000 | $1,003,000.00 | 134,693 | 2025-08-20 | Filing | |
| $15.50 | 4,250 | $65,875.00 | 7,500 | 2019-03-06 | Filing | |
| $16.00 | 3,250 | $52,000.00 | 3,250 | 2019-03-06 | Filing | |
| $18.00 | 58,534 | $1,053,612.00 | 2,662,180 | 2016-05-11 | Filing | |
| $18.00 | 191,466 | $3,446,388.00 | 2,603,646 | 2016-05-11 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $17.38 | 31 | $538.78 | 105,184 | 2025-10-01 | Filing | |
| $17.38 | 1,871 | $32,517.98 | 55,266 | 2025-10-01 | Filing | |
| $14.02 | 7,462 | $104,617.24 | 106,062 | 2025-07-23 | Filing | |
| $9.82 | 1,022 | $10,036.04 | 95,369 | 2025-07-01 | Filing | |
| $9.95 | 2,503 | $24,904.85 | 57,137 | 2025-07-02 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 153,456 | $2,650,185 | 0% | |
| 2. | 150,393 | $2,597,287 | 0.09% | |
| 3. | 64,850 | $1,119,844 | 0.01% | |
| 4. | 64,220 | $1,109,079 | 0.01% | |
| 5. | 26,600 | $459,382 | 0% |
News See All
Intellia Therapeutics (NTLA) Soars to New High as Analysts Trigger 'Buy'
“Rising earnings estimates and the consequent rating upgrade fundamentally mean an improvement in the company’s underlying business.
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q2 2025 Earnings Call Transcript
Operator: Good morning, and welcome to Intellia Therapeutics Second Quarter 2025 Financial Results Conference Call. My name is Drew, and I will be your conference operator today.
Citizens JMP Maintains Neutral Stance on Intellia Despite Positive Lonvo-z Data
Intellia Therapeutics, Inc. (NASDAQ:NTLA) ranks among the best CRISPR stocks to buy. Citizens JMP reaffirmed its Market Perform rating on Intellia Therapeutics, Inc. (NASDAQ:NTLA) on June 17.
Top 10 CRISPR Stocks to Buy Now
Innovation is a hallmark of the biopharmaceutical sector, which is fueled by the demand for novel therapies to address unresolved medical needs.
Intellia Reports Positive 3-Year Lonvo-z Data in HAE Trial at EAACI Congress
Intellia Therapeutics, Inc. (NASDAQ:NTLA) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds.
11 Best Genomics Stocks to Buy According to Hedge Funds
Genomics is the study of genes and how they operate.
Intellia Therapeutics, Inc. (NTLA) Backed by H.C. Wainwright for 237% Upside Potential
Intellia Therapeutics, Inc. (NASDAQ:NTLA) is among the best NASDAQ stocks under $50 to buy. Analysts at H.C. Wainwright have reaffirmed a Buy rating on Intellia Therapeutics, Inc.
10 Best NASDAQ Stocks Under $50 to Buy
In this era where everyone is striving for the best, whether it be something in daily life or technology, the stock market is no exception.
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q1 2025 Earnings Call Transcript
Operator: Good morning, and welcome to Intellia' First Quarter 2025 Financial Results Conference Call. My name is Drew, and I will be your conference operator today.
Hedge Fund Resource Center Billionaire Hedge Funds
